Trial Profile
A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients With Advanced or Metastatic Cholangiocarcinoma With FGFR2 Gene Fusions or Other FGFR Genetic Alterations Who Failed or Are Intolerant to Platinum-based Chemotherapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Infigratinib (Primary)
- Indications Cholangiocarcinoma
- Focus Registrational; Therapeutic Use
- Sponsors Novartis Pharmaceuticals; QED Therapeutics
- 29 Jun 2023 Status changed from completed to discontinued.
- 22 Jun 2022 Status changed from active, no longer recruiting to completed.
- 18 May 2022 Systemic review literature of two phase 2 studies assessing efficacy and safety of infigratinib for the treatment of advanced CCA were presented at the 27th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.